(Q35435376)

8 August 2017

Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C (English)

1 reference

8 August 2017

1 reference

1 reference

1 reference

15

Mario Rizzetto

1 reference

8 August 2017

Rinaldo Pellicano

1

1 reference

8 August 2017

Antonio Craxi

2

1 reference

8 August 2017

Piero-Luigi Almasio

3

1 reference

8 August 2017

Mario Valenza

4

1 reference

8 August 2017

Giovanna Venezia

5

1 reference

8 August 2017

Alfredo Alberti

6

1 reference

8 August 2017

Silvia Boccato

7

1 reference

8 August 2017

Luigi Demelia

8

1 reference

8 August 2017

Orazio Sorbello

9

1 reference

8 August 2017

Antonino Picciotto

10

1 reference

8 August 2017

Francesco Torre

11

1 reference

8 August 2017

Gaetano Ideo

12

1 reference

8 August 2017

Carlo Cattaneo

13

1 reference

8 August 2017

Mara Berrutti

14

1 reference

8 August 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

World Journal of Gastroenterology

8 August 2017

1 reference

8 August 2017

11

1 reference

8 August 2017

29

1 reference

8 August 2017

4484-4489

1 reference

Safety of interferon beta treatment for chronic HCV hepatitis

8 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398696

Understudied populations with hepatitis C.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398696

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398696

Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398696

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398696

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398696

IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes-associated tyrosine phosphatase autoantigens.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398696

Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398696

Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398696

Re-treatment with interferon-beta of patients with chronic hepatitis C virus infection

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398696

Side effects of therapy of hepatitis C and their management

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398696

Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398696

A pilot study of recombinant interferon beta-1a for the treatment of chronic hepatitis C.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398696

The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398696

Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398696

Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers

26 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16052676

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Neutralizing and binding antibodies to IFN-beta: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-beta preparations

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16052676

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3748/WJG.V11.I29.4484

1 reference

8 August 2017

1 reference

8 August 2017

1 reference